197846-06-3

Usage

Chemical Properties

Solid

InChI:InChI=1/C6H5BrO3/c1-9-6(8)4-2-3-10-5(4)7/h2-3H,1H3

Upstream product

• 197846-05-2 2-bromofuran-3-carboxylic acid 
• 77-78-1 dimethyl sulfate 
• 488-93-7 3-Furoic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 1334394-42-1 4-[3-(Toluene-4-sulfonyloxymethyl)furan-2-yl]-piperidine-1-carboxylic Acid t-Butyl Ester 
• 868286-61-7 [3-(methoxycarbonyl)-2-furyl]boronic acid 

Relevant academic research and scientific papers

Photostable Helical Polyfurans

This report describes the design and synthesis of a new class of polyfurans bearing ester side chains. The macromolecules can be synthesized using catalyst-transfer polycondensation, providing precise control over molecular weight and molecular weight distribution. Such obtained furan ester polymers are significantly more photostable than their alkyl analogues owing to the electron-withdrawing nature of the attached subunit. Most interestingly, they spontaneously fold into a compact π-stacked helix, yielding a complex multilayer cylindrical nanoparticle with a hollow, rigid, conjugated core composed of the polyfuran backbone and a soft, insulating outer layer formed by the ester side chains. The length of polymer side chains dictates the outer diameter of such nanoparticles, which for the hexyl ester groups used in the present study is equal to ～2.3 nm. The inner cavity of the conjugated core is lined with oxygen atoms, which set its effective diameter to 0.4 nm. Furthermore, installation of bulkier, branched chiral ester side chains on the repeat unit yields structures that, upon change of solvent, can reversibly transition between an ordered chiral helical folded and disordered unfolded state.

Revisiting the Quinoxalinedione Scaffold in the Construction of New Ligands for the Ionotropic Glutamate Receptors

More than two decades ago, the quinoxalinedione scaffold was shown to act as an α-amino acid bioisoster. Following extensive structure-activity relationship (SAR) studies, the antagonists DNQX, CNQX, and NBQX in the ionotropic glutamate receptor field were identified. In this work, we revisit the quinoxalinedione scaffold and explore the incorporation of an acid functionality in the 6-position. The SAR studies disclose that by this strategy it was possible to tune in iGluR selectivity among the AMPA, NMDA, and KA receptors, and to some extent also obtain full receptor subtype selectivity. Highlights of the study of 44 new analogues are compound 2m being a high affinity ligand for native AMPA receptors (IC50= 0.48 μM), analogues 2e,f,h,k,v all displayed selectivity for native NMDA receptors, and compounds 2s,t,u are selective ligand for the GluK1 receptor. Most interestingly, compound 2w was shown to be a GluK3-preferring ligand with full selectivity over native AMPA, KA and NMDA receptors.

Room-Temperature Gold-Catalysed Arylation of Heteroarenes: Complementarity to Palladium Catalysis

Tailoring of the pre-catalyst, the oxidant and the arylsilane enables the first room-temperature, gold-catalysed, innate C?H arylation of heteroarenes. Regioselectivity is consistently high and, in some cases, distinct from that reported with palladium ca

Supramolecular control of selectivity in hydroformylation of vinyl arenes: Easy access to valuable β-aldehyde intermediates

Go against the flow! A rationally designed regioselective hydroformylation catalyst, [Rh/L], in which noncovalent ligand-substrate interactions allow the unprecedented reversal of selectivity from the typical α-aldehyde to the otherwise unfavored product β-aldehyde, is reported. This catalytic system opens up novel and sustainable synthetic pathways to important intermediates for the fine-chemicals industry.

1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS

The invention relates to compounds of formula I: where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Antimuscarinic 3-(2-Furanyl)quinuclidin-2-ene derivatives: Synthesis and structure-activity relationships

A series of 25 derivatives of the muscarinic antagonist 3-(2- furanyl)quinuclidin-2-ene (4) was synthesized and evaluated for muscarinic and antimuscarinic properties. Substitution at all three positions of the furan ring has been investigated. The affini